Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–13. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi: 10.1016/j.jhep.2022.08.021.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi: 10.1016/j.jhep.2021.11.030.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379–379. doi: 10.1200/JCO.2022.40.4_suppl.379.
   Web of Science ®Google Scholar
• Qin S, Kudo M, Meyer T, et al. LBA36 final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Annals of Oncology. 2022;33: s 1402–S1403. doi: 10.1016/j.annonc.2022.08.033.
   Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi: 10.1016/S1470-2045(21)00604-5.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi: 10.1016/S1470-2045(22)00326-6.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784. doi: 10.7326/M14-2385.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617. doi: 10.1177/0272989X12458724.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171. doi: 10.1016/j.jclinepi.2010.03.016.
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22(7):977–990. doi: 10.1016/S1470-2045(21)00252-7.
   PubMed Web of Science ®Google Scholar
• Qin S, Chan LS, Gu S, et al. LBA35 camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Annals of Oncology. 2022;33: s 1401–S1402. doi: 10.1016/j.annonc.2022.08.032.
   Web of Science ®Google Scholar
• Dawson LA, Winter K, Knox J, et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. Stereotactic body radiation therapy (SBRT) Followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937). International Journal of Radiation Oncology Biology Physics. 2022;114(5):1057. doi: 10.1016/j.ijrobp.2022.09.002.
   Web of Science ®Google Scholar
• Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in First-Line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, Open-Label, Parallel-Controlled phase II-III trial. J Clin Oncol. 2021;39(27):3002–3011. doi: 10.1200/JCO.21.00163.
   PubMed Web of Science ®Google Scholar
• Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–1174. doi: 10.1016/j.jhep.2019.08.006.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):684–691. doi: 10.1016/j.jhep.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer. 2019;19(1):954. doi: 10.1186/s12885-019-6198-8.
   PubMed Web of Science ®Google Scholar
• Jouve JL, Lecomte T, Bouché O, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(3):516–522. doi: 10.1016/j.jhep.2019.04.021.
   PubMed Web of Science ®Google Scholar
• Assenat E, Pageaux GP, Thézenas S, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer. 2019;120(9):896–902. doi: 10.1038/s41416-019-0443-4.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019;5(11):1582–1588. doi: 10.1001/jamaoncol.2019.2792.
   PubMed Web of Science ®Google Scholar
• Yen CJ, Kim TY, Feng YH, et al. A phase I/randomized phase II study to evaluate the safety, pharmacokinetics, and efficacy of nintedanib versus sorafenib in asian patients with advanced hepatocellular carcinoma. Liver Cancer. 2018;7(2):165–178. doi: 10.1159/000486460.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase II Open-Label Multi-Institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the First-Line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94(6):329–339. doi: 10.1159/000485384.
   PubMed Web of Science ®Google Scholar
• Tak WY, Ryoo BY, Lim HY, et al. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east asian patients. Invest New Drugs. 2018;36(6):1072–1084. doi: 10.1007/s10637-018-0658-x.
   PubMed Web of Science ®Google Scholar
• Palmer DH, Ma YT, Peck-Radosavljevic M, et al. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in european patients with advanced hepatocellular carcinoma. Br J Cancer. 2018;118(9):1162–1168. doi: 10.1038/s41416-018-0051-8.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424–432. doi: 10.1016/S2468-1253(18)30078-5.
   PubMed Web of Science ®Google Scholar
• Azim HA, Omar A, Atef H, et al. Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109–119. doi: 10.2147/JHC.S169285.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol. 2016;27(11):2090–2096. doi: 10.1093/annonc/mdw323.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016;64(3):774–784. doi: 10.1002/hep.28600.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–566. doi: 10.1200/JCO.2013.53.7746.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, He AR, et al. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol. 2015;63(4):896–904. doi: 10.1016/j.jhep.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–179. doi: 10.1200/JCO.2013.54.3298.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524. doi: 10.1200/JCO.2012.48.4410.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–4075. doi: 10.1200/JCO.2012.45.8372.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi: 10.1056/NEJMoa1717002.
   PubMed Web of Science ®Google Scholar
• Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(7):559–568. doi: 10.1016/S2468-1253(21)00109-6.
   PubMed Web of Science ®Google Scholar
• Ryoo BY, Cheng AL, Ren Z, et al. Randomised phase 1b/2 trial of tepotinib vs sorafenib in asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer. 2021;125(2):200–208. doi: 10.1038/s41416-021-01380-3.
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Sukeepaisarnjaroen W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919889001. doi: 10.1177/1758835919889001.
   Web of Science ®Google Scholar
• Chan SL, Schuler M, Kang YK, et al. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41(1):189. doi: 10.1186/s13046-022-02383-5.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, et al. First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular ­carcinoma. Cancer Discov. 2019;9(12):1696–1707. doi: 10.1158/2159-8290.CD-19-0555.
   PubMed Web of Science ®Google Scholar
• Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer. 2019;8(6):413–426. doi: 10.1159/000503254.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203–222. doi: 10.1038/s41575-022-00704-9.
   PubMed Web of Science ®Google Scholar
• Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564.
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Merle P, et al. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 2022;33: s 1401. doi: 10.1016/j.annonc.2022.08.031.
   Web of Science ®Google Scholar
• Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi: 10.1200/JCO.21.01963.
   PubMed Web of Science ®Google Scholar
• Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455–464. doi: 10.1148/radiol.211545.
   PubMed Web of Science ®Google Scholar
• Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150–160. doi: 10.1200/JCO.21.00608.
   PubMed Web of Science ®Google Scholar